October 23, 2023 11:56 AM EDTUpdated 01:57 PM
R&D
Cell/Gene Tx
Manufacturing

BioN­Tech CAR-T man­u­fac­tur­ing change leads to fresh da­ta with vac­cine com­bo, with reg­is­tra­tional tri­al plans: #ES­MO23

Reynald Castañeda

Deputy Editor

MADRID — BioN­Tech is back with new da­ta to sup­port its BNT211 pro­gram in sol­id tu­mors af­ter a man­u­fac­tur­ing tweak. The com­pa­ny is now re­view­ing plans …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times